Literature DB >> 3026004

Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.

F Moosdeen, J Keeble, J D Williams.   

Abstract

Many species of gram-negative bacteria produce chromosomal beta-lactamases that can be induced to high-level expression by exposure to beta-lactam antibiotics. Fifty-four strains of Escherichia coli, Enterobacter, Proteus, Citrobacter, and Morganella were examined for beta-lactamase inducibility by clavulanic acid, sulbactam, YTR 830, ampicillin, and cefoxitin. Cefoxitin proved to be the most potent inducer, affecting most of the strains of Enterobacter and Morganella. Clavulanic acid induced 30% of all strains studied. Sulbactam and YTR 830 did not induce measurable levels of beta-lactamases. Inhibition of some chromosomal beta-lactamases by sulbactam and YTR 830 was demonstrated, whereas inhibitory activity by clavulanic acid was found only in Proteus and Citrobacter.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3026004     DOI: 10.1093/clinids/8.supplement_5.s562

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

1.  Evaluation of the automated phoenix system for potential routine use in the clinical microbiology laboratory.

Authors:  J-L Donay; D Mathieu; P Fernandes; C Prégermain; P Bruel; A Wargnier; I Casin; F X Weill; P H Lagrange; J L Herrmann
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

2.  In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.

Authors:  M D Kitzis; B Ferré; A Coutrot; J F Acar; L Gutmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

Review 3.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

Review 4.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

5.  Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Authors:  N A Kuck; N V Jacobus; P J Petersen; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 6.  Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.

Authors:  P Charbonneau
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

7.  Influence of beta-lactamase inhibitors on the potency of their companion drug with organisms possessing class I enzymes.

Authors:  S J Cavalieri; C C Sanders; C New
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 8.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Effect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase.

Authors:  K Bush; R K Flamm; S Ohringer; S B Singer; R Summerill; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Diverse potential of beta-lactamase inhibitors to induce class I enzymes.

Authors:  D A Weber; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.